UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of psychiatric medications on sleep and sleep disorders

CNS & neurological disorders drug targets, 2007-02, Vol.6 (1), p.17-29

2007

Volltextzugriff (PDF)

A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder

The journal of clinical psychiatry, 2007-05, Vol.68 (5), p.677-688

2007

Volltextzugriff (PDF)

A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia

Journal of clinical psychopharmacology, 2019-07, Vol.39 (4), p.318-328

2019

Volltextzugriff (PDF)

Results of a randomized double‐blind study evaluating luvadaxistat in adults with Friedreich ataxia

Annals of clinical and translational neurology, 2021-06, Vol.8 (6), p.1343-1352

2021

Volltextzugriff (PDF)

Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia

The journal of clinical psychiatry, 2003-10, Vol.64 (10), p.1224-1229

2003

Volltextzugriff (PDF)

Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study

The journal of clinical psychiatry, 2003-07, Vol.64 (7), p.785-792

2003

Volltextzugriff (PDF)

P387. PRAX-114, An Extrasynaptic-Preferring GABAA Receptor Positive Allosteric Modulator: A Phase 2 Trial Evaluating Multiple Dose Safety, Tolerability, and Preliminary Efficacy in Major Depressive Disorder

Biological psychiatry (1969), 2022-05, Vol.91 (9), p.S243-S244

2022

Volltextzugriff (PDF)

INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia

Schizophrenia research, 2024-08, Vol.270, p.249-257

2024

Volltextzugriff (PDF)

PRAX-114 Produces Robust Increases in EEG Beta Frequency Power, a Translational Biomarker of GABA-A Receptor Modulation, Without Dose-Limiting Sedation

Biological psychiatry (1969), 2021-05, Vol.89 (9), p.S337-S337

2021

Volltextzugriff (PDF)

Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute Schizophrenia

Journal of clinical psychopharmacology, 2019-11, Vol.39 (6), p.575-582

2019

Volltextzugriff (PDF)

A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson’s Disease

Clinical drug investigation, 2018-06, Vol.38 (6), p.509-517

2018

Volltextzugriff (PDF)

Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-831, a Selective D-amino Acid Oxidase Inhibitor, in Healthy Volunteers (P2.1-015)

Neurology, 2019-04, Vol.92 (15_supplement)

2019

Volltextzugriff (PDF)

A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia

Journal of psychopharmacology (Oxford), 2019-10, Vol.33 (10), p.1237-1247

2019

Volltextzugriff (PDF)

New Approaches for the Treatment of Sleep Disorders

Advances in Pharmacology, 2009, Vol.57, p.187-235

2009

Volltextzugriff (PDF)

A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity

The international journal of neuropsychopharmacology, 2020-05, Vol.23 (5), p.287-299

2020

Volltextzugriff (PDF)

Systematic identification and classification of adverse events in human research

Contemporary clinical trials, 2006-06, Vol.27 (3), p.295-303

2006

Volltextzugriff (PDF)

First-in-Human Assessment of the Novel PDE2A PET Radiotracer super( 18)F-PF-05270430

The Journal of nuclear medicine (1978), 2016-09, Vol.57 (9), p.1388-1388

2016

Volltextzugriff (PDF)

First-in-Human Assessment of the Novel PDE2A PET Radiotracer ^sup 18^F-PF-05270430

The Journal of nuclear medicine (1978), 2016-09, Vol.57 (9), p.1388

2016

Volltextzugriff (PDF)

First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18 F-PF-05270430

Journal of Nuclear Medicine, 2016-09, Vol.57 (9), p.1388-1395

2016

Volltextzugriff (PDF)

An open-label trial of nefazodone in high comorbidity panic disorder

The journal of clinical psychiatry, 1996-06, Vol.57 (6), p.245

1996

Volltextzugriff (PDF)

The Effects of Antidepressants on Sleep

The Psychiatric times, 2012-06, Vol.29 (6), p.17

2012

Volltextzugriff (PDF)

First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430

The Journal of nuclear medicine (1978), 2016-09, Vol.57 (9), p.1388-1395

2016

Volltextzugriff (PDF)

The effects of antidepressants on sleep: the good and the bad

The Psychiatric times, 2012-06, Vol.29 (6), p.17

2012

Volltextzugriff (PDF)

Poster #212 RESULTS OF A PHASE 2A PROOF-OF-CONCEPT TRIAL WITH A PDE10A INHIBITOR IN THE TREATMENT OF ACUTE EXACERBATION OF SCHIZOPHRENIA

Schizophrenia research, 2012-04, Vol.136, p.S262-S262

2012

Volltextzugriff (PDF)

MODEL BASED META-ANALYSIS OF POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS NEGATIVE SUBSCALE) IN STABLE CHRONIC SCHIZOPHRENIC PATIENTS FOR MONOTHERAPY AND ADJUNCT THERAPIES

Schizophrenia research, 2010-04, Vol.117 (2), p.409-409

2010

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(35)
Buchkapitel
(3)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Humans
(20)
Psychiatry
(20)
Adult
(15)
Female
(15)
Male
(14)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Pharmacology & Pharmacy
(11)
Pharmacology. Drug Treatments
(11)
Psychology. Psychoanalysis. Psychiatry
(11)
Double-Blind Method
(10)
Middle Aged
(10)
Neuropharmacology
(10)
Psychopharmacology
(10)
Treatment Outcome
(6)
Adolescent
(5)
Dopamine
(5)
Drug Therapy
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of psychiatric medications on sleep and sleep disorders

A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder

A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia

Results of a randomized double‐blind study evaluating luvadaxistat in adults with Friedreich ataxia

Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia

Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study

P387. PRAX-114, An Extrasynaptic-Preferring GABAA Receptor Positive Allosteric Modulator: A Phase 2 Trial Evaluating Multiple Dose Safety, Tolerability, and Preliminary Efficacy in Major Depressive Disorder

INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia

PRAX-114 Produces Robust Increases in EEG Beta Frequency Power, a Translational Biomarker of GABA-A Receptor Modulation, Without Dose-Limiting Sedation

Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute Schizophrenia

A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson’s Disease

Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-831, a Selective D-amino Acid Oxidase Inhibitor, in Healthy Volunteers (P2.1-015)

A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia

New Approaches for the Treatment of Sleep Disorders

A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity

Systematic identification and classification of adverse events in human research

First-in-Human Assessment of the Novel PDE2A PET Radiotracer super( 18)F-PF-05270430

First-in-Human Assessment of the Novel PDE2A PET Radiotracer ^sup 18^F-PF-05270430

First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18 F-PF-05270430

An open-label trial of nefazodone in high comorbidity panic disorder

The Effects of Antidepressants on Sleep

First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430

The effects of antidepressants on sleep: the good and the bad

Poster #212 RESULTS OF A PHASE 2A PROOF-OF-CONCEPT TRIAL WITH A PDE10A INHIBITOR IN THE TREATMENT OF ACUTE EXACERBATION OF SCHIZOPHRENIA

MODEL BASED META-ANALYSIS OF POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS NEGATIVE SUBSCALE) IN STABLE CHRONIC SCHIZOPHRENIC PATIENTS FOR MONOTHERAPY AND ADJUNCT THERAPIES

Suchergebnisse filtern